Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis
Authors:
- 8 June 2016
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 27 (11) , 3239-3249
Abstract
Summary Retrospective claims analysis indicated that high levels of daily and cumulative doses of systemic glucocorticoids were associated with elevated fracture risk in a large cohort of new RA patients under age 65. Heightened risk began to decline within months of discontinuation. Findings were similar among patients age <50 years. Introduction We evaluated the impact of systemic glucocorticoid exposure on fracture risk among relatively young patients with new-onset rheumatoid arthritis (RA). Methods Using administrative data, we identified 42,127 RA patients diagnosed January 1, 2005–December 31, 2012, age 18–64 years, with benefits coverage for ≥12 months before RA diagnosis. Follow-up extended to clinical fracture, cancer diagnosis, or December 31, 2012. Glucocorticoid users were new to therapy. Fracture incidence rates (IR) were stratified by glucocorticoid exposure expressed as prednisone equivalent doses. Cox’s proportional hazards models estimated fracture risk adjusted for demographics and baseline clinical characteristics to assess dose-response relationships with current (daily) and prior (cumulative) dose, and by time since discontinuation. Results Most patients (85 %) had glucocorticoid exposure. Exposed and unexposed patients were demographically similar (74 % female; mean age 49.7 and 48.8 years); 1 % had prior fracture. Fracture IRs (95 % confidence intervals) were 5 to 9 per 1000 person-years at doses <15 mg/day, 16.0 (11.0, 22.6) at doses ≥15 mg/day, and 13.4 (10.7, 16.7) at cumulative doses ≥5400 mg. Adjusted fracture risk was approximately 2-fold higher at highest dose levels compared with 0 mg/day current daily dose and <675 mg cumulative dose, respectively. Fracture risk was 29 % lower at 60–182 days post-discontinuation compared with ongoing use and was similar to unexposed patients by 12 months. Findings were similar among patients age <50 years. Conclusions Among younger, new-onset RA patients, fracture risk was significantly elevated at high levels of daily and cumulative dose, and was similar to unexposed patients by 12 months post-discontinuation.Keywords
Funding Information
- Amgen
- Amgen
This publication has 42 references indexed in Scilit:
- Trends in Fracture Incidence: A Population-Based Study Over 20 YearsJournal of Bone and Mineral Research, 2013
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Identification and Validation of Vertebral Compression Fractures Using Administrative Claims DataMedical Care, 2009
- Glucocorticoids: action and new therapeutic insights in rheumatoid arthritisCurrent Opinion in Rheumatology, 2007
- High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient studyBone, 2006
- Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patientsArthritis & Rheumatism, 2005
- The population risk of fractures attributable to oral corticosteroidsPharmacoepidemiology and Drug Safety, 2005
- Safety of Inhaled CorticosteroidsProceedings of the American Thoracic Society, 2004
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- Effect of short-term glucocorticoids on serum osteocalcin in healthy young menJournal of Bone and Mineral Research, 1988